EX-99.1 2 d97546dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patients BBO-8520 monotherapy continues to show highly competitive ORR in the 2L+ KRASG12C inhibitor-naïve NSCLC with ORR of 63% (26/41), disease control rate (DCR) of 100% (41/41) and no grade 3 liver enzyme elevations BBO-11818 and BBO-10203 combination cohorts enrolling in KRAS-mutant CRC and PDAC $344.1 million in cash, cash equivalents and marketable securities as of June 30, 2026, provides runway into 2028 SOUTH SAN FRANCISCO, Calif., September 8, 2026 - BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced new clinical data for KRASG12C inhibitor BBO-8520 and the strategic prioritization of (i) BBO-8520 in combination with checkpoint inhibitor in 2L+ KRASG12C inhibitor-experienced non-small c…
Open exhibit ↗Current Report · Items 8.01, 9.01 · 8-K
BridgeBio Oncology Therapeutics, Inc.
BBOTNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Matters On September 8, 2026, BridgeBio Oncology Therapeutics, Inc. (the “Company”) issued a press release titled “BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorp…
Company context
Helix Acquisition Corp. II (Nasdaq: HLXB) is a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. Helix Acquisition Corp. II raised $184 million in its initial public offering on February 9, 2024. Helix is sponsored by affiliates of Cormorant Asset Management and is headquartered in Boston, Massachusetts.
Current securities
Disclosure sections
Item 8.01Item 8.01 - Other Events
Filed exhibits (2)
EX-99.2 3 d97546dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Corporate Update September 2026 BBOT Next-Generation RAS-Pathway Therapeutics Forward-Looking Statements ThispresentationisbeingmadebyBridgeBioOncologyTherapeutics, Inc.(“BBOT”orthe“Company”).Certainstatementsincludedinthispresentationthatarenothistoricalfactsareforward-lookingstatements. Forward-lookingstatementsgenerallyareaccompaniedbywordssuchas“believe,”“may,”“will,”“estimate,”“continue,”“anticipate,”“intend,”“expect,”“should,”“would,”“plan,”“predict,”“potential,”“seem,”“seek,”“future,”“outlook”andsimilarexpressionsthatpredictorindicatefutureeventsortrendsorthatarenotstatementsofhistoricalmatters. TheCompanyintendstheseforward-lookingstatementstobecoveredbythesafeharborprovisionsforforward-lookingstatementscontainedinSection27AoftheSecuritiesActof1933, asamended, andSection21EoftheSecuritiesExchangeActof1934, asamended. Thesestatements, includingexpressorimpliedstatementsrelatingtotheclinicalandtherapeuticpotentialofBBOT’sproductcandidates, includingasmonotherapyorincombinationwithothertherapeutics, BBOT’splanstocontinueandexpanditsclinicaltrials, anticipateddatareadoutsandthetimingoftheseevents, themarketopportuni…
Open exhibit ↗